Search Results - "Bowden, Charles H."

A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults by Winslow, David H, Bowden, Charles H, DiDonato, Karen P, McCullough, Pamela A

“…To evaluate safety and efficacy of phentermine 15 mg plus extended-release topiramate 92 mg for treatment of moderate to severe obstructive sleep apnea (OSA)…”
Get full text

Avanafil for the Treatment of Erectile Dysfunction: A Multicenter, Randomized, Double-Blind Study in Men With Diabetes Mellitus by Goldstein, Irwin, MD, Jones, LeRoy A., MD, Belkoff, Laurence H., DO, Karlin, Gary S., MD, Bowden, Charles H., MD, Peterson, Craig A., MS, Trask, Brenda A., BS, Day, Wesley W., PhD

“…Abstract Objective To prospectively assess the safety and effectiveness of the investigational phosphodiesterase 5 inhibitor avanafil to treat erectile…”
Get full text

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study by Garvey, W Timothy, Ryan, Donna H, Look, Michelle, Gadde, Kishore M, Allison, David B, Peterson, Craig A, Schwiers, Michael, Day, Wesley W, Bowden, Charles H

“…Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has…”
Get full text

Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2 by Davidson, Michael H., MD, Tonstad, Serena, MD, Oparil, Suzanne, MD, Schwiers, Michael, MS, Day, Wesley W., PhD, Bowden, Charles H., MD

“…The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine…”
Get full text

A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy by Mulhall, John P, Burnett, Arthur L, Wang, Run, McVary, Kevin T, Moul, Judd W, Bowden, Charles H, DiDonato, Karen, Shih, Winnie, Day, Wesley W

“…We evaluated the safety and efficacy of 100 and 200 mg avanafil for the treatment of adult males with erectile dysfunction after bilateral nerve sparing…”
Get more information

A Randomized, Double‐Blind, Placebo‐Controlled Evaluation of the Safety and Efficacy of Avanafil in Subjects with Erectile Dysfunction by Goldstein, Irwin, McCullough, Andrew R., Jones, LeRoy A., Hellstrom, Wayne J., Bowden, Charles H., DiDonato, Karen, Trask, Brenda, Day, Wesley W.

“…Phosphodiesterase type 5 (PDE5) inhibitors have become standard treatment for erectile dysfunction (ED). To prospectively evaluate the safety and efficacy of…”
Get full text

Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2) by Davidson, Michael H, Tonstad, Serena, Oparil, Suzanne, Schwiers, Michael, Day, Wesley W, Bowden, Charles H

“…The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine…”
Get full text

Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study by Hellstrom, Wayne J.G, Kaminetsky, Jed, Belkoff, Laurence H, Goldstein, Irwin, Tursi, James P, Uy, Jonathan, Peterson, Craig A, Bowden, Charles H, Day, Wesley W

“…Purpose We examined the therapeutic effects of avanafil 15 minutes after dosing in men with mild to severe erectile dysfunction. Materials and Methods This…”
Get full text

WEIGHT LOSS AND CARDIOVASCULAR RISK REDUCTION OVER 2 YEARS WITH CONTROLLED-RELEASE PHENTERMINE-TOPIRAMATE by Davidson, Michael, Bowden, Charles H, Day, Wesley W

Get full text

Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index greater than or equal to 27 kg/m2 by Davidson, Michael H, Tonstad, Serena, Oparil, Suzanne, Schwiers, Michael, Day, Wesley W, Bowden, Charles H

“…The aim of this analysis was to evaluate changes in cardiovascular risk factors in obese patients with dyslipidemia and/or hypertension receiving phentermine…”
Get full text

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study123 by Garvey, W Timothy, Ryan, Donna H, Look, Michelle, Gadde, Kishore M, Allison, David B, Peterson, Craig A, Schwiers, Michael, Day, Wesley W, Bowden, Charles H

“…Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has…”
Get full text

Efficacy of Avanafil 15 Minutes after Dosing in Men with Erectile Dysfunction: A Randomized, Double-Blind, Placebo Controlled Study by Bakırcıoğlu, Emre

“…Phosphodiesterase type 5 (PDE 5) inhibitors are currently first-line medical treatment for erectile dysfunction (ED). PDE 5 inhibitors are differentiated by…”
Get full text